Mahboob U. Rahman

8.8k citations

85 papers · 5.8k indexed · 2 hit papers · h-index 38

Rheumatology top 0.1%
- Rheumatoid Arthritis Research and Therapies 45
- Systemic Lupus Erythematosus Research 17
- Spondyloarthritis Studies and Treatments 9
Hematology top 0.5%
- Autoimmune and Inflammatory Disorders Research 29
Genetics top 1%
- Chronic Lymphocytic Leukemia Research 13
Immunology top 2%
Immunology and Allergy top 5%
Pulmonary and Respiratory Medicine
- Vasculitis and related conditions 7
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 5
Microbiology
- Reproductive tract infections research 4

Co-authors: Elizabeth C. Hsia Sudha Visvanathan Hyon K. Choi Eric L. Matteson Mittie K. Doyle Weichun Xu Paul E. Drawz Susan S. Jick
Cited by: Rheumatology Hematology Genetics
Partner nations: United States United Kingdom Canada

In The Last Decade

Mahboob U. Rahman

82 papers receiving 5.6k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2009 Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial
2008 Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study

Peers

Countries citing papers authored by Mahboob U. Rahman

Since Specialization

Citations

This map shows the geographic impact of Mahboob U. Rahman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mahboob U. Rahman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mahboob U. Rahman more than expected).

Fields of papers citing papers by Mahboob U. Rahman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mahboob U. Rahman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mahboob U. Rahman. The network helps show where Mahboob U. Rahman may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Mahboob U. Rahman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mahboob U. Rahman Line = papers co-authored together Mahboob U. Rahman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Family History of Kidney Failure, APOL1 Risk Variants, Social Determinants of Health, and Risk of CKD Progression: Findings From the CRIC Study Wei Lin,Alexander R. Chang,Deidra C. Crews,Bessie A. Young,Lawrence J. Appel,(unknown),Amanda H. Anderson,Jing Chen,Debbie L. Cohen,Laura M. Dember,Alan Go,James P. Lash,Mahboob U. Rahman,Panduranga S. Rao,Vallabh O. Shah,Mark Unruh	2026	0
2	Chronic kidney disease prevalence and outcomes in patients with type 2 diabetes or prediabetes at high cardiovascular risk: results from the CINEMA program Sanjana Datla,Zainab Albar,Elke Eaton,Jodie Porges,Matthew Nennstiel,Claire Sullivan,Lloyd A. Greene,Sadeer Al‐Kindi,Elizabeth A. Montgomery,Aparna Padiyar,Mikhail Kosiborod,Melissa Magwire,Mahboob U. Rahman,Sanjay Rajagopalan,Ian J. Neeland	2025	1
3	Biological evaluation of antimicrobial activity of Calotropis procera against a range of bacteria Hayat Bilal,Imdad Ali,Shahab Uddin,Ibrahim N. Khan,Anwar Said,Mahboob U. Rahman,Abdul Majid Khan,Abdul Bari Shah,Ayaz Ali Khan	2020	7
4	Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies Rubén Burgos‐Vargas,Mario H. Cardiel,Daniel Xibillé,César Pacheco‐Tena,Virginia Pascual‐Ramos,Carlos Abud‐Mendoza,Ehab Mahgoub,Mahboob U. Rahman,Haiyun Fan,Ricardo Rojo,Erika G. García,Karina Talita de Oliveira Santana	2017	2
5	The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis Daniel E. Fürst,Jonathan Kay,Mary Chester Wasko,Edward Keystone,Arthur Kavanaugh,Atul Deodhar,Frederick T. Murphy,Jeanette H. Magnus,Elizabeth C. Hsia,Benjamin Hsu,Stephen Xu,Mahboob U. Rahman,Mittie K. Doyle	2013	26
6	Magnetic resonance imaging assessments of patients with RA and their association with clinical and radiographic outcomes Paul Emery,D. van der Heijde,Mikkel Østergaard,Philip G. Conaghan,Mark C. Genovese,E C Keystone,R Fleischmann,Wen‐Xiu Xu,Shengqing Xu,E. C. Hsia,Mahboob U. Rahman	2011	1
7	Assessment of inflammation and damage by MRI in established RA patients with Methotrexate inadequate response receiving Golimumab: Results of the GO-FORWARD trial Philip G. Conaghan,P. Emery,Mikkel Østergaard,Ed Keystone,Mark C. Genovese,Lars Klareskog,W. Xu,E. C. Hsia,Mahboob U. Rahman	2011	2
8	Golimumab and Methotrexate combinatation therapy significantly improves synovitis, osteitis and bone erosion compared to Methotrexate alone - A magnetic resonance imaging study of Methotrexate-naïve rheumatoid arthritis patients Mikkel Østergaard,Paul Emery,Philip G. Conaghan,R. Fleischmann,W. Xu,E. C. Hsia,Mahboob U. Rahman	2011	2
9	GOLIMUMAB AND RADIOGRAPHIC PROGRESSION IN RHEUMATOID ARTHRITIS: RESULTS OF GO-BEFORE AND GO-FORWARD STUDIES P. Emery,R. Fleischmann,Désirée van der Heijde,Edward Keystone,Mark C. Genovese,Philip G. Conaghan,E. C. Hsia,W. Xu,Anna Baratelle,Anna Beutler,Mahboob U. Rahman,Go-Before Go-Forward	2011	1
10	GOLIMUMAB INHIBITS PROGRESSION OF RADIOGRAPHIC DAMAGE IN PATIENTS WITH PSORIATIC ARTHRITIS: 52 WEEK RESULTS FROM THE GO-REVEAL STUDY Arthur Kavanaugh,D. van der Heijde,C. Chattopadhyay,D. Gladman,P.J. Mease,Iain B. McInnes,G.G. Krueger,W. Xu,Mahboob U. Rahman,Julie Zrubek,Anna Baratelle,Anna Beutler,Go-Reveal Investigators	2010	9
11	Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trialbreakdown → Josef S Smolen,Jonathan Kay,Mittie K. Doyle,Robert Landewé,Eric L. Matteson,J. Wollenhaupt,Norman Gaylis,Frederick T. Murphy,Jeffrey Neal,Yiying Zhou,Sudha Visvanathan,Elizabeth C. Hsia,Mahboob U. Rahman	2009	423
12	Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab Jürgen Braun,Désirée van der Heijde,Mittie K. Doyle,Chenglong Han,Atul Deodhar,Robert D. Inman,Kurt de Vlam,Gerd R Burmester,Filip Van den Bosch,Stephen Xu,Sudha Visvanathan,Mahboob U. Rahman	2009	27
13	Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Studybreakdown → Edward Keystone,Mark C. Genovese,Lars Klareskog,E. C. Hsia,Stephen Hall,Pedro C. Miranda,J Pazdur,Sang‐Cheol Bae,William Palmer,Julie Zrubek,Maria Wiekowski,Sudha Visvanathan,Zhixian Wu,Mahboob U. Rahman	2008	432
14	Improvement in DAS28 response through one-year of golimumab treatment in patients with active RA despite treatment with methotrexate: A phase II, randomized, double blind, placebo controlled, dose ranging trial Jonathan Kay,Patrick Durez,Eric L. Matteson,B. Dasgupta,Peter Nash,Stephen Hall,E. C. Hsia,P. Chiruvolu,Jia Han,Mahboob U. Rahman	2007	2
15	Pharmacokinetics and Safety of Golimumab, a Fully Human Anti‐TNF‐α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis Honghui Zhou,Haishan Jang,Roy Fleischmann,Esther Bouman‐Thio,Zhenhua Xu,Joseph C. Marini,Charles Pendley,Qun Jiao,Gopi Shankar,Stanley J. Marciniak,Stanley Cohen,Mahboob U. Rahman,Daniel Baker,Mary Ann Mascelli,Hugh M. Davis,Daniel E. Everitt	2007	149
16	Das28 responses in patients with active rheumatoid arthritis who received golimumab and methotrexate: A randomized, double-blind, placebo-controlled phase 2 trial Julia Kay,Eric L. Matteson,B. Dasgupta,Peter Nash,P. Durezs,Steve Hall,Julia Han,Mahboob U. Rahman	2006	3
17	Glucocorticoid use, other associated factors, and the risk of tuberculosis Susan S. Jick,Eric S. Lieberman,Mahboob U. Rahman,Hyon K. Choi	2006	330
18	Autoimmune vestibulo–cochlear disorders Mahboob U. Rahman,Dennis S. Poe,Hyon K. Choi	2001	31
19	Etanercept Therapy for Immune-mediated Cochleovestibular Disorders: Preliminary Results in a Pilot Study Mahboob U. Rahman,Dennis S. Poe,Hyon K. Choi	2001	50
20	Nature and Transcriptional Role of Catalytic Subunits of Yeast Mitochondrial cAMP-Dependent Protein Kinase Mahboob U. Rahman,Alan P. Hudson	1995	10

About Mahboob U. Rahman

Mahboob U. Rahman is a scholar working on Rheumatology, Hematology and Genetics, having authored 85 papers that have together received 5.8k indexed citations. Recurring topics across this work include Rheumatoid Arthritis Research and Therapies (45 papers), Autoimmune and Inflammatory Disorders Research (29 papers), Systemic Lupus Erythematosus Research (17 papers), Chronic Lymphocytic Leukemia Research (13 papers), Spondyloarthritis Studies and Treatments (9 papers), Vasculitis and related conditions (7 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Reproductive tract infections research (4 papers). The work is most often cited by research in Rheumatology (3.8k citations), Hematology (1.6k citations) and Genetics (912 citations). Mahboob U. Rahman has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include Elizabeth C. Hsia, Sudha Visvanathan, Hyon K. Choi, Eric L. Matteson, Mittie K. Doyle, Weichun Xu, Paul E. Drawz, Susan S. Jick, Jonathan Kay and Edward Keystone.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact